Similar articles for PMID: 22960984

Year	Number of Results
1995	1
1996	2
1998	1
1999	2
2001	1
2002	1
2003	1
2006	1
2007	2
2009	4
2010	2
2011	1
2012	4
2013	6
2014	3
2015	9
2016	9
2017	6
2018	9
2019	10
2020	10
2021	11
2022	5
2023	8
2024	1

1

Progress in cystic fibrosis and the CF Therapeutics Development Network.

Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW. Rowe SM, et al. Thorax. 2012 Oct;67(10):882-90. doi: 10.1136/thoraxjnl-2012-202550. Thorax. 2012. PMID: 22960984 Free PMC article.

2

The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases.

Goss CH, Mayer-Hamblett N, Kronmal RA, Ramsey BW. Goss CH, et al. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1505-28. doi: 10.1016/s0169-409x(02)00163-1. Adv Drug Deliv Rev. 2002. PMID: 12458158 Review.

3

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.

Mayer-Hamblett N, Boyle M, VanDevanter D. Mayer-Hamblett N, et al. Thorax. 2016 May;71(5):454-61. doi: 10.1136/thoraxjnl-2015-208123. Epub 2016 Feb 22. Thorax. 2016. PMID: 26903594 Free PMC article. Review.

4

Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.

Southern KW, Patel S, Sinha IP, Nevitt SJ. Southern KW, et al. Cochrane Database Syst Rev. 2018 Aug 2;8(8):CD010966. doi: 10.1002/14651858.CD010966.pub2. Cochrane Database Syst Rev. 2018. PMID: 30070364 Free PMC article. Updated. Review.

5

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.

Harutyunyan M, Huang Y, Mun KS, Yang F, Arora K, Naren AP. Harutyunyan M, et al. Am J Physiol Lung Cell Mol Physiol. 2018 Apr 1;314(4):L529-L543. doi: 10.1152/ajplung.00465.2017. Epub 2017 Dec 14. Am J Physiol Lung Cell Mol Physiol. 2018. PMID: 29351449 Free PMC article. Review.

6

The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network.

Pearson K, Mayer-Hamblett N, Goss CH, Retsch-Bogart GZ, VanDalfsen JM, Burks P, Rosenbluth D, Clancy JP, Hoffman A, Nichols DP. Pearson K, et al. J Cyst Fibros. 2021 Mar;20(2):195-197. doi: 10.1016/j.jcf.2020.12.007. Epub 2020 Dec 15. J Cyst Fibros. 2021. PMID: 33349583 Free PMC article.

7

Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.

Warnock L, Gates A. Warnock L, et al. Cochrane Database Syst Rev. 2023 Apr 12;4(4):CD001401. doi: 10.1002/14651858.CD001401.pub4. Cochrane Database Syst Rev. 2023. PMID: 37042825 Free PMC article. Review.

8

[Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].

Chinese Experts Cystic Fibrosis Consensus Committee; Chinese Alliance for Rare Lung Diseases; Chinese Alliance for Rare Diseases, Bronchiectasis-China. Chinese Experts Cystic Fibrosis Consensus Committee, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2023 Apr 12;46(4):352-372. doi: 10.3760/cma.j.cn112147-20221214-00971. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 36990700 Chinese.

9

Aslam AA, Sinha IP, Southern KW. Aslam AA, et al. Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD012040. doi: 10.1002/14651858.CD012040.pub3. Cochrane Database Syst Rev. 2023. PMID: 36866921 Free PMC article. Review.

10

Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.

Becq F. Becq F. Drugs. 2010 Feb 12;70(3):241-59. doi: 10.2165/11316160-000000000-00000. Drugs. 2010. PMID: 20166764 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year